RYBREVANT

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland, Romania, United Kingdom, United States

Active ingredients

The drug RYBREVANT contains one active pharmaceutical ingredient (API):

1 Amivantamab UNII 0JSR7Z0NB6 - AMIVANTAMAB

Amivantamab is a low-fucose, fully-human IgG1-based EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating EGFR Exon 20 insertion mutations. Amivantamab binds to the extracellular domains of EGFR and MET. Amivantamab disrupts EGFR and MET signalling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumour growth and progression. Read about Amivantamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RYBREVANT Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC
RYBREVANT Solution for injection		MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX18		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1868542
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 156701
Country: FR	Base de données publique des médicaments	Identifier(s): 61371536
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9033
Country: IT	Agenzia del Farmaco	Identifier(s): 049823014
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093863
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100463491
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68416001
Country: US	FDA, National Drug Code	Identifier(s): 57894-501